dichloroacetonitrile: by-product of water chlorination; structure given in first source
ID Source | ID |
---|---|
PubMed CID | 18177 |
CHEMBL ID | 1485360 |
CHEBI ID | 82444 |
SCHEMBL ID | 1180554 |
MeSH ID | M0147077 |
Synonym |
---|
3018-12-0 |
dichloromethyl cyanide |
dichloroacetonitrile |
nsc60511 |
nsc-60511 |
acetonitrile, dichloro- |
NCGC00091123-01 |
ccris 942 |
brn 1739029 |
nsc 60511 |
einecs 221-159-4 |
hsdb 6861 |
inchi=1/c2hcl2n/c3-2(4)1-5/h2 |
dichloroacetonitrile, analytical standard |
dichloroacetonitrile, 98% |
2,2-dichloroacetonitrile |
D2510 |
AKOS000120181 |
NCGC00091123-03 |
NCGC00091123-02 |
C19395 |
4-02-00-00506 (beilstein handbook reference) |
o0l64v63m9 , |
unii-o0l64v63m9 |
NCGC00257772-01 |
dtxcid701562 |
cas-3018-12-0 |
dtxsid3021562 , |
tox21_200218 |
2,2-bis(chloranyl)ethanenitrile |
A820249 |
FT-0624703 |
dichloroacetonitrile [hsdb] |
dichloroacetonitrile [iarc] |
CHEMBL1485360 |
SCHEMBL1180554 |
CHEBI:82444 , |
c2hcl2n |
J-802184 |
mfcd00040886 |
dichloroacetonitrile; dichloromethyl cyanide; nsc 60511 |
dichloroacetonitrile 100 microg/ml in cyclohexane |
dcan |
Q27155945 |
AMY3929 |
D90075 |
dichloro-acetonitrile |
EN300-19387 |
Dichloroacetonitrile (DCAN) is a typical nitrogenous disinfection by-product (N-DBP) and its toxicity on aquatic animals is investigated for the first time.
Excerpt | Reference | Relevance |
---|---|---|
"Dichloroacetonitrile (DCAN) is a typical nitrogenous disinfection by-product (N-DBP) and its toxicity on aquatic animals is investigated for the first time. " | ( Acute toxicity of dichloroacetonitrile (DCAN), a typical nitrogenous disinfection by-product (N-DBP), on zebrafish (Danio rerio). Chen, W; Dong, J; Jiang, F; Lin, T; Zhou, D, 2016) | 2.21 |
"Dichloroacetonitrile (DCAN), is a member of haloacetonitrile group and detected in drinking water supplies as a by-product of chlorination process. " | ( Possible role of hydroxyl radicals in the oxidation of dichloroacetonitrile by Fenton-like reaction. Mohamadin, AM, 2001) | 2 |
Excerpt | Reference | Relevance |
---|---|---|
" The present study was designed to investigate the potential adverse effects of DCAN on zebrafish." | ( Acute toxicity of dichloroacetonitrile (DCAN), a typical nitrogenous disinfection by-product (N-DBP), on zebrafish (Danio rerio). Chen, W; Dong, J; Jiang, F; Lin, T; Zhou, D, 2016) | 0.77 |
Excerpt | Relevance | Reference |
---|---|---|
" Based on initial dose-response experiment, DCAN (14 mg/kg/day) was administered orally to pregnant mice at gestation day (GD) 6, till GD 15." | ( Dichloroacetonitrile induces oxidative stress and developmental apoptotic imbalance in mouse fetal brain. Abdel-Naim, AB; El-Demerdash, E; Esmat, A; Ghoneim, AI; Khalifa, AE, 2012) | 1.82 |
" Increased Cl2/NH2Cl dosage and reaction time improved the formation of CHCl3 and DCAce." | ( Chlorination and chloramination of tetracycline antibiotics: disinfection by-products formation and influential factors. Deng, J; Gao, N; Ma, Y; Shao, Y; Zhou, S; Zhu, S, 2014) | 0.4 |
" Tests were carried out to determine the effect of the reaction time (5-120 h), water pH (4-10), total organic carbon (TOC) content (2-8 mg L(-1)), chlorine dosage (3-25 mg L(-l)), water temperature (5-30 degrees C) and usual coagulants on HANsFP in the Dez River water." | ( The formation potential of haloacetonitriles in the Dez River water, Iran. Ahmadi, M; Ramavandi, B, ) | 0.13 |
" All kinds of DBPs detected increased with the dosage of increasing chlorine, but the increases slowed down when the dosage was higher than 2 mg ." | ( [Formation of Disinfection By-Products During Chlor(am)ination of Danjiangkou Reservoir Water and Comparison of Disinfection Processes]. Cheng, T; Chu, WH; Xia, SJ; Xu, B; Zhang, MS; Zhang, TY, 2015) | 0.42 |
" Chlorine dosage had slight influence on DBP yield in this study." | ( Reduction of disinfection by-product precursors in reservoir water by coagulation and ultrafiltration. Gao, B; Li, R; Ma, D; Wang, F; Wang, Q; Yue, Q, 2016) | 0.43 |
" In conclusion, the present study indicated that STZ diabetic rats are resistant to DCAN-induced neurotoxicity at the dosage and with the dosage schedule in 28-day subacute toxicity test." | ( Tolerance to dichloroacetonitrile-induced neurotoxicity in streptozotocin-induced diabetic rats. Dong, Y; Li, F; Lu, R; Shen, H; Tian, W; Wang, S; Xing, G; Yin, S, 2017) | 0.82 |
Class | Description |
---|---|
aliphatic nitrile | Any nitrile derived from an aliphatic compound. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
interleukin 8 | Homo sapiens (human) | Potency | 74.9780 | 0.0473 | 49.4806 | 74.9780 | AID651758 |
15-lipoxygenase, partial | Homo sapiens (human) | Potency | 31.6228 | 0.0126 | 10.6917 | 88.5700 | AID887 |
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 26.8096 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 14.9502 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 30.0274 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 33.8889 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259381; AID743035; AID743036; AID743040; AID743042; AID743063 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 17.7828 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 31.6228 | 0.0013 | 7.7625 | 44.6684 | AID2120 |
progesterone receptor | Homo sapiens (human) | Potency | 5.3045 | 0.0004 | 17.9460 | 75.1148 | AID1346784 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 6.0019 | 0.0002 | 14.3764 | 60.0339 | AID720691 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 45.5629 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 37.7493 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 60.0193 | 0.3758 | 27.4851 | 61.6524 | AID743220 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 40.4569 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743069; AID743075; AID743080; AID743091 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 44.6684 | 0.0010 | 24.5048 | 61.6448 | AID588535 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 24.2713 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743191 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 66.7801 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
activating transcription factor 6 | Homo sapiens (human) | Potency | 60.0193 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 21.2957 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 63.0957 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 53.3972 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 60.0193 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 24.2531 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743202; AID743219 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 5.8655 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 29.8296 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 38.6819 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID651743 |
Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 29.8296 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 33.4915 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 74.9285 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
Ataxin-2 | Homo sapiens (human) | Potency | 74.9285 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (3.23) | 18.7374 |
1990's | 3 (4.84) | 18.2507 |
2000's | 9 (14.52) | 29.6817 |
2010's | 37 (59.68) | 24.3611 |
2020's | 11 (17.74) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (33.67) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 63 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |